New radioactive drug targets FAP-Positive tumors in early trial

NCT ID NCT07213791

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times

Summary

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims to find safe doses and see if the drug can shrink tumors. About 241 participants will be followed for up to 5 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Amsterdam UMC - Locatie VUmc
NOT_YET_RECRUITING

Amsterdam, 1081 HV, Netherlands
BAMF Health Inc.
RECRUITING

Grand Rapids, Michigan, 49503, United States
Barbara Ann Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Baylor College of Medicine
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Beth Israel Deaconess Medical Center
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Biogenix Molecular, LLC
RECRUITING

Miami, Florida, 33165, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITING

New York, New York, 10065, United States
Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710, United States
Erasmus MC
NOT_YET_RECRUITING

GE Rotterdam, 3015, Netherlands
Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
Fudan University Zhongshan Hospital
NOT_YET_RECRUITING

Shanghai, 200032, China
Hoag Memorial Hospital Presbyterian
RECRUITING

Newport Beach, California, 92663, United States
Indiana University (IU) School of Medicine
RECRUITING

Indianapolis, Indiana, 46202, United States
Kyoto University Hospital
NOT_YET_RECRUITING

Kyoto, 606-8507, Japan
Maastricht University Medical Center
NOT_YET_RECRUITING

Maastricht, 6229 HX, Netherlands
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Mayo Clinic - Rochester
NOT_YET_RECRUITING

Rochester, Minnesota, 55905, United States
Moffitt
NOT_YET_RECRUITING

Tampa, Florida, 33612, United States
National Cancer Center Hospital East
NOT_YET_RECRUITING

Chiba, 277-8577, Japan
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
NOT_YET_RECRUITING

Amsterdam, 1066 CX, Netherlands
New York University (NYU) Clinical Cancer Center
NOT_YET_RECRUITING

New York, New York, 10016, United States
Stanford University Medical Center
RECRUITING

Stanford, California, 94305, United States
Stichting Radboud Universitair Medisch Centrum
NOT_YET_RECRUITING

Nijmegen, 6525 GA, Netherlands
Texas Oncology - DFW (Sammons CC)
NOT_YET_RECRUITING

Dallas, Texas, 75246, United States
United Theranostics
RECRUITING

Glen Burnie, Maryland, 21061, United States
Universitaetsklinikum Essen
NOT_YET_RECRUITING

Essen, 45147, Germany
Universitair Medisch Centrum Utrecht
NOT_YET_RECRUITING

Utrecht, 3584CX, Netherlands
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Wisconsin - Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53792, United States
Washington University School of Medicine in St. Louis
NOT_YET_RECRUITING

St Louis, Missouri, 63110, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LY4337713 (a radioligand therapy given intravenously)

What this could lead to

If it works, this could point toward a new treatment option for several hard-to-treat cancers that have a specific protein called FAP.

What could go wrong

This is a very early Phase 1 trial, so the main goals are safety and dosing—not yet proving it works. The drug may cause side effects or fail to shrink tumors.

Conditions

The condition(s) this trial relates to.

breast neoplasm cholangiocarcinoma colorectal neoplasm Esophageal Neoplasms gastric neoplasm ovarian cancer Pancreatic Intraductal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS BREAST NEOPLASMS CHOLANGIOCARCINOMA COLORECTAL NEOPLASMS ESOPHAGEAL NEOPLASMS OVARIAN NEOPLASMS PANCREATIC INTRADUCTAL NEOPLASMS STOMACH NEOPLASMS